Inhibiteur Cdk4 III

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Reversible: no

Product does not compete with ATP.

Cell permeable: yes

Primary TargetCdk4

Target IC₅₀: 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A

General description

A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC₅₀ = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC₅₀ = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).

A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC₅₀ = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC₅₀ = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Ryu, C.K., et al. 2000. Bioorg. Med. Chem. Lett.10, 461.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)